What Is Dileucine? The Science Behind the Next-Gen Leucine Peptide

• TL;DR: Dileucine is a dipeptide made of two leucine molecules bonded together, and it behaves very differently from free leucine once ingested.
• It is absorbed intact into the bloodstream via the PepT1 transporter, a pathway that free amino acids cannot use, meaning it reaches circulation as an actual peptide, not just as leucine.
• A 2021 double-blind randomized controlled trial found that 2g of dileucine significantly increased muscle protein synthesis rates over 180 minutes, while the same dose of free leucine did not produce a statistically significant increase.
• Dileucine dosing aligns directly with clinical research: Wise Choice Supplements Dileucine delivers 2000mg per serving, matching the exact dose used in the landmark human trial.

What Dileucine Actually Is

Dileucine is a dipeptide: two leucine amino acid molecules joined by a single peptide bond, written chemically as Leu-Leu. It is not a modified leucine analog or a synthetic compound. It is the natural product of leucine-leucine condensation, and it exists in small quantities in protein-rich foods that have been hydrolyzed during digestion.

As a supplement, dileucine is produced as a concentrated, purified powder. That small structural difference from free leucine changes how the body absorbs and uses it.

The critical distinction between dileucine and free leucine is not what they contain. Both deliver leucine to the body. The distinction is how they are absorbed and what happens in between. That difference has direct consequences for muscle protein synthesis.

Why Free Leucine Has a Ceiling

Leucine has been the most studied amino acid in sports nutrition for good reason. It functions as the primary anabolic trigger for mTORC1, the mechanistic target of rapamycin complex 1, which is the master regulator of muscle protein synthesis. When plasma leucine rises above a certain threshold, it signals mTORC1 to drive the ribosomal machinery that builds new muscle proteins.

The problem is that free leucine, when taken as a supplement or consumed from protein, goes through the standard free amino acid transport system in the small intestine. Transporters like LAT1 (SLC7A5) and 4F2hc move leucine across the intestinal epithelium and into the portal circulation. This works. But it has limitations.

The Leucine Threshold Problem

Research has established that leucine must reach a minimum plasma concentration to activate mTORC1 signaling meaningfully. Below that threshold, very little anabolic signaling occurs. Above it, signaling plateaus. This means that taking more leucine does not linearly increase the anabolic response. There is a dose ceiling.

Additionally, free amino acid transporters are shared across many amino acids. Leucine competes with isoleucine, valine, phenylalanine, and others for the same transport slots. Under conditions where multiple amino acids are present, as after a mixed protein meal, leucine absorption can be blunted or delayed relative to what you might expect from a bolus dose.

This is where the dipeptide form offers a fundamentally different route.

The PepT1 Absorption Advantage

Dipeptides and tripeptides are absorbed through a completely separate transporter: PepT1, encoded by the SLC15A1 gene. PepT1 is a proton-coupled oligopeptide transporter expressed predominantly in the brush border membrane of the small intestinal epithelium. It evolved specifically to absorb short peptides from digested protein.

Here is what makes PepT1 absorption different from free amino acid absorption:

• PepT1 does not compete with free amino acids for transport capacity. Dileucine and free leucine use entirely separate transporter systems, meaning they can be absorbed simultaneously without blocking each other.
• PepT1 transport is driven by an inward proton gradient (the intestinal lumen is acidic relative to the enterocyte interior), making it highly efficient even at low luminal peptide concentrations.
• Critically, a portion of the absorbed dipeptide escapes intracellular hydrolysis and enters the portal circulation as an intact peptide. It does not get broken down into free amino acids before reaching the bloodstream.

That last point is what makes dileucine research so interesting. The peptide itself circulates. It is not just a vehicle for delivering leucine. It is a bioactive molecule in its own right, and its presence in plasma may trigger anabolic responses that free leucine alone cannot replicate.

How Dileucine Activates mTORC1

To understand why dileucine may outperform leucine, you need a working model of how mTORC1 detects leucine availability in the first place.

The cellular leucine-sensing machinery centers on Sestrin2 (SESN2), a protein that acts as a direct leucine sensor. When leucine is scarce, Sestrin2 binds to and inhibits GATOR2, a protein complex that normally keeps mTORC1 active. When leucine is abundant, it binds directly to Sestrin2, releasing GATOR2 inhibition and allowing mTORC1 to activate. The Rag GTPase heterodimers then recruit mTORC1 to the lysosomal surface, where it is activated by Rheb (Wolfson et al., 2016, PMID 26449471).

mTORC1 activation drives phosphorylation of p70S6K (which in turn phosphorylates rpS6, promoting ribosome biogenesis) and 4E-BP1 (which releases the translation initiation factor eIF4E to drive cap-dependent translation of muscle protein mRNAs). When dileucine circulates intact in plasma, it provides two leucine residues in a single molecular unit and may engage additional signaling nodes beyond those activated by free leucine alone. The Paulussen 2021 data shows the functional consequence: meaningfully greater MPS at the same 2g dose.

What the Research Actually Shows

The most important piece of human evidence on dileucine comes from Paulussen et al. (2021), published in the Journal of Applied Physiology (PMID 34323596). This was a double-blind, randomized crossover controlled trial, the strongest study design available in nutrition research.

Study Design

Ten healthy young men (mean age 23 years) consumed either 2g of free leucine or 2g of dileucine in two separate trial visits. Using stable isotope tracer methodology, specifically primed continuous infusions of l-[ring-13C6]phenylalanine and l-[15N]phenylalanine, the researchers measured both myofibrillar protein synthesis (MPS) rates and mixed muscle protein breakdown (MPB) rates over 180 minutes. Blood samples and muscle biopsies were collected at multiple time points.

Key Findings

• Plasma leucine: Both conditions produced similar plasma leucine net area under the curve (AUC), confirming that dileucine and leucine deliver equivalent leucine to the bloodstream. The difference in MPS outcomes was not due to more leucine reaching circulation.
• Plasma dileucine: The dileucine group showed a significantly greater plasma dileucine AUC compared to the leucine group (P = 0.013), confirming that dileucine is absorbed intact and circulates as an intact peptide.
• mTOR signaling markers: Phosphorylation of Akt, rpS6, and p70S6K increased over time under both conditions, confirming that both interventions engaged the mTORC1 signaling pathway.
• Muscle protein synthesis: Cumulative MPS over 0-180 minutes was 0.075 +/- 0.032 percent per hour in the dileucine condition versus 0.047 +/- 0.029 percent per hour in the leucine condition (P = 0.023). The dileucine-induced MPS increase was statistically significant. The leucine condition was not.
• Muscle protein breakdown: MPB did not differ significantly between conditions, meaning dileucine's advantage is on the synthesis side, not through reduced breakdown.

The authors' conclusion: dileucine ingestion elevated plasma dileucine concentrations and stimulated muscle protein turnover by increasing MPS rates in healthy young men. They noted this was "the first insights into the effects of dipeptides on human protein metabolism."

At the same dose of 2g, free leucine did not produce a statistically significant increase in MPS. Dileucine did. That is the core finding.

Ready to Try the Dose the Research Used

Wise Choice Supplements Dileucine delivers exactly 2000mg per serving as a pure, Eurofins-tested powder. That is the dose used in the Paulussen 2021 trial. Get Dileucine here and see why researchers are calling dipeptides the next frontier in muscle nutrition science.

Dileucine vs. Leucine: The Practical Summary

For a detailed breakdown of the head-to-head comparison, see our full guide on dileucine vs. leucine. Here is the high-level version:

• Delivery mechanism: Free leucine uses the LAT1/4F2hc amino acid transporter. Dileucine uses PepT1. These are separate pathways that do not compete.
• Circulating form: Free leucine reaches the blood as leucine. Dileucine reaches the blood partly as free leucine and partly as intact Leu-Leu peptide. That intact peptide appears to matter.
• MPS response at 2g: In the only human trial comparing them head-to-head at equal doses, dileucine produced a statistically significant MPS increase. Leucine did not.
• mTOR signaling: Both activate the pathway. The difference appears to be in the magnitude of the downstream protein synthesis response, not in whether signaling occurs at all.
• Protein breakdown: Neither intervention significantly reduced MPB. Dileucine's advantage is in driving synthesis, not suppressing breakdown.

Who Benefits from a Dileucine Supplement

The research was conducted in healthy young men, so that is the population with the clearest evidence. But the mechanistic rationale for dileucine extends to several groups:

Resistance-Trained Athletes

Athletes who already consume sufficient protein can use dileucine to maximize the anabolic response from individual meals or post-workout nutrition windows. Because dileucine uses a separate absorption pathway from free amino acids, it can be added to a protein shake or protein meal without competing with other amino acids in that meal for transport.

Older Adults Targeting Muscle Maintenance

Anabolic resistance, the blunted MPS response to protein and leucine that develops with aging, is well documented. Research suggests the leucine threshold required to activate mTORC1 may be higher in older adults. Dileucine, by providing both a leucine bolus and an intact circulating peptide, may offer a more potent anabolic signal than free leucine at the same dose. Clinical trials specifically in older adults have not been published as of 2026, but the mechanistic rationale is strong.

Athletes Managing Caloric Restriction

Dileucine taken between meals creates a discrete anabolic pulse without requiring a full protein meal. It delivers 2000mg of leucine-equivalent content in a small powder serving, making it practical for athletes in a caloric deficit who cannot hit multiple large protein meals per day.

How to Use Dileucine: Dosing and Timing

The human clinical evidence supports a dose of 2g per serving. This is not an arbitrarily rounded number. It is the exact dose used in Paulussen et al. 2021, the only published randomized controlled trial in humans. Going below 1.5g likely leaves the dose below the effective threshold. Doses above 3g have not been specifically studied for additional benefit in humans.

Timing: Post-resistance exercise is the most studied window for leucine supplementation, as mTOR signaling is primed by mechanical loading. The Paulussen study was conducted at rest, which confirms that dileucine's MPS effect does not require exercise as a primer. Post-training or between meals are both valid windows. Pure dileucine powder dissolves in water, requires no fat for absorption, and can be added to a protein shake without competing with whey or BCAA absorption due to the separate PepT1 transport pathway.

If you want a supplement that has both mechanistic plausibility and direct human trial data behind it, Wise Choice Supplements Dileucine at 2000mg per serving, third-party tested by Eurofins, is the cleanest way to act on the current science.

Frequently Asked Questions

What is dileucine made of?

Dileucine is a dipeptide consisting of two leucine amino acid molecules joined by a peptide bond, written as Leu-Leu. It is produced by peptide synthesis and is sold as a pure powder supplement. It is not a plant extract or a novel chemical entity. It is a naturally occurring dipeptide that the body produces in small amounts during protein digestion.

Is dileucine the same as leucine?

No. They share the same amino acid building block but are structurally different compounds. Free leucine is a single amino acid. Dileucine is a dipeptide with a distinct molecular structure. They are absorbed through different transporters, they produce different plasma profiles, and in the only head-to-head human trial, they produced different magnitudes of muscle protein synthesis response at the same 2g dose.

How much dileucine should I take?

The dose used in the published human trial (Paulussen et al. 2021) was 2g. This is the only dose with direct human MPS data behind it. Wise Choice Supplements delivers 2000mg per serving, matching the research dose exactly. There is no current evidence supporting a higher dose producing meaningfully greater effects, and no dose-ranging study in humans has been published as of 2026.

When should I take dileucine?

The clinical trial was conducted at rest, not post-exercise, which means the MPS-stimulating effect was observed independent of exercise. That said, post-resistance training is a logical window given the established synergy between mechanical loading and leucine-mediated mTORC1 activation. Taking it within 30-60 minutes of training, or between meals to create additional anabolic pulses, are both reasonable approaches. No specific timing comparison studies for dileucine in humans have been published.

Can I take dileucine with protein powder?

Yes. Because dileucine uses the PepT1 dipeptide transporter and the amino acids in protein powder use separate free amino acid transporters (such as LAT1), they do not compete for absorption. You can add dileucine powder directly to a protein shake without reducing the absorption of either. This is one of the practical advantages of the PepT1 absorption mechanism.

Is dileucine safe?

Leucine is one of the best-studied amino acids in human nutrition with an established safety record. Dileucine delivers leucine plus a small intact peptide and was well tolerated in the published human trial with no adverse events reported. As with any supplement, individuals with kidney disease or metabolic conditions should consult a physician before use. Quality matters: the Wise Choice Supplements dileucine is Eurofins tested for identity and purity.

Sources

1. Paulussen KJM, Alamilla RA, Salvador AF, McKenna CF, Askow AT, Fang HY, Li Z, Ulanov AV, Paluska SA, Rathmacher JA, Jager R, Purpura M, Burd NA. Dileucine ingestion is more effective than leucine in stimulating muscle protein turnover in young males: a double blind randomized controlled trial. J Appl Physiol. 2021 Sep 1;131(3):1111-1122. doi: 10.1152/japplphysiol.00295.2021. PMID: 34323596. PubMed
2. Wolfson RL, Chantranupong L, Saxton RA, Shen K, Scaria SM, Cantor JR, Sabatini DM. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2016 Jan 8;351(6268):43-8. doi: 10.1126/science.aab2674. PMID: 26449471. PubMed
3. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017 Mar 9;168(6):960-976. doi: 10.1016/j.cell.2017.02.004. PMID: 28283069. PubMed
4. Adibi SA. The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology. 1997 Feb;112(2):332-40. doi: 10.1053/gast.1997.v112.pm9024293. PMID: 9024293. PubMed
5. Norton LE, Layman DK. Leucine regulates translation initiation of protein synthesis in skeletal muscle after exercise. J Nutr. 2006 Feb;136(2):533S-537S. doi: 10.1093/jn/136.2.533S. PMID: 16424141. PubMed
6. Brandsch M. Drug transport via the intestinal peptide transporter PepT1. Curr Opin Pharmacol. 2013 Dec;13(6):881-7. doi: 10.1016/j.coph.2013.08.004. PMID: 23981904. PubMed